FDA head warns of backlash against pharma innovators in attack on “anti-competitive” patent strategies

US Food & Drug Administration (FDA) commissioner Scott Gottlieb has condemned the acquisition of large numbers of follow-on patent rights by branded drugs makers to extend their market monopolies. This patent thicketing, he argued, is one of several…

Get unlimited access to all IAM content